Maybe you can help me. How did they go from preclin straight to PhII? Are they assuming (or modeling) a dose (or concentration) from their preclin work? Is this normal for optical solution product development?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.